
New weekly @AnnSurgOncol featured article: Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review. ow.ly/3Lwi50VCXJG #ASOFeaturedArticle

melanoma surgeon, surgical educator, father, husband and fisherman

New weekly @AnnSurgOncol featured article: Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review. ow.ly/3Lwi50VCXJG #ASOFeaturedArticle

👏👏👏
Honored to present our work on gender and seniority bias in surgical resident evaluations at #ASE2025. Grateful for the chance to engage with such a thoughtful and inspiring community @EmorySurgery @Surg_Education

#AudioVisualAbstract : Results of a Randomized Clinical Study of #Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable #Pancreatic #DuctalAdenocarcinoma rdcu.be/eloqh @SyedAAhmad5

May Issue: Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with #Melanoma . @OlofssonBagge @C_ODonoghueMD @alabama_surgonc @MarkFariesMD @jzager99 rdcu.be/ekVZg @DorianGarciaMD @SyedAAhmad5

#AudioVisualAbstract : Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive #BreastCancer : A Retrospective Analysis rdcu.be/ek3b4 @belenmerck @SyedAAhmad5

May Issue: Clinical Significance of Coiled-Coil Domain-Containing Protein 25 Expression in #Esophageal #SquamousCellCarcinoma rdcu.be/ek3eF @lindSLUe @SyedAAhmad5

Featured: Strategies for Recurrent #ColorectalLiver Metastases Based on Prognostic Factors and Resectability: Potential Benefit of #MultidisciplinaryTreatment . @Kosuke_Koba_yh8 ow.ly/z35w50VON9C @_BrainyMD_ @SyedAAhmad5

#AudioVisualAbstract : Endoscopic Evaluation of #PathologicalCompleteResponse Using #DeepNeuralNetwork in #EsophagealCancer Patients Who Received Neoadjuvant Chemotherapy—Multicenter Retrospective Study from Four Japanese Esophageal Centers rdcu.be/elfqy @SyedAAhmad5

Thank you for your excellent talks and for sharing your experiences with our residents in rocking chair rounds!
Enjoyed being back in my “home” #BeanTown #Boston as combined @MGHSurgery @MGHCancerCenter Visiting Professor. ❤️seeing old friends & mentors, as well as spending time with next generation of #surgical #leaders. Big 🙏 to Dr. Lillemoe for being as kind & gracious as always. 🎁

Join us on April 22, 2025, for the Emory at Grady Faculty Awards. This ceremony will recognize outstanding faculty contributions and achievements. Hope to see you there!279

April Issue: Risk-Prediction Models for Clinical Decision-Making in #Sarcoma Care: An International Survey Among Soft-Tissue Sarcoma Clinicians @lvanbodegomvos rdcu.be/ehSLh @DorianGarciaMD @SyedAAhmad5

.@EmoryMedicine @EmoryatGrady @emorygradydoc @grannysurgeon @EmorySurgery This year’s SURG-20 class. Notice something special? Yep! All women. Truly an honor to teach these amazing future doctors @wiserpodcast

The latest SSO consensus statement urges caution with gene expression profiling (GEP) for primary cutaneous melanoma. Given evolving evidence, GEP is recommended as an investigational tool in research or clinical trials. Read more: @AnnSurgOncol: surgonc.org/annals-of-surgic…

I get asked how GEP tests should be used in cutaneous melanoma at every meeting. Great to see this consensus statement out in print. @SocSurgOnc
The latest SSO consensus statement urges caution with gene expression profiling (GEP) for primary cutaneous melanoma. Given evolving evidence, GEP is recommended as an investigational tool in research or clinical trials. Read more: @AnnSurgOncol: surgonc.org/annals-of-surgic…


SSO announces publication of its 1st consensus statement, Assessing the Evidence For and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma. Developed by melanoma specialists around four clinical questions on GEP testing for primary CM. ow.ly/OSAa50TWrhM